Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | REPL |
---|---|---|
09:32 ET | 10219 | 10.35 |
09:34 ET | 6019 | 10.205 |
09:36 ET | 1331 | 10.14 |
09:38 ET | 4427 | 9.95 |
09:39 ET | 4530 | 10.19 |
09:41 ET | 600 | 10.1754 |
09:43 ET | 1090 | 10.24 |
09:45 ET | 6793 | 10.37 |
09:48 ET | 2090 | 10.355 |
09:50 ET | 1100 | 10.338 |
09:52 ET | 3085 | 10.27 |
09:54 ET | 1253 | 10.185 |
09:56 ET | 2170 | 10.23 |
09:57 ET | 1200 | 10.27 |
09:59 ET | 13207 | 10.33 |
10:01 ET | 547 | 10.29 |
10:03 ET | 3528 | 10.231 |
10:06 ET | 1462 | 10.4 |
10:08 ET | 15587 | 10.47 |
10:10 ET | 3200 | 10.554 |
10:12 ET | 1000 | 10.57 |
10:14 ET | 3936 | 10.475 |
10:15 ET | 2630 | 10.44 |
10:17 ET | 21308 | 10.25 |
10:19 ET | 2592 | 10.31 |
10:21 ET | 1100 | 10.35 |
10:24 ET | 1000 | 10.345 |
10:26 ET | 1303 | 10.3 |
10:28 ET | 1958 | 10.33 |
10:30 ET | 1000 | 10.39 |
10:32 ET | 4161 | 10.26 |
10:33 ET | 2249 | 10.3 |
10:35 ET | 1100 | 10.32 |
10:37 ET | 2054 | 10.26 |
10:39 ET | 2656 | 10.27 |
10:42 ET | 1473 | 10.27 |
10:44 ET | 2911 | 10.235 |
10:46 ET | 1800 | 10.25 |
10:48 ET | 427 | 10.245 |
10:50 ET | 2588 | 10.09 |
10:51 ET | 200 | 10.06 |
10:53 ET | 6718 | 10.04 |
10:55 ET | 455 | 10.08 |
10:57 ET | 500 | 10.05 |
11:00 ET | 1712 | 9.96 |
11:02 ET | 899 | 9.9597 |
11:04 ET | 324 | 9.94 |
11:06 ET | 414 | 9.95 |
11:08 ET | 2306 | 9.93 |
11:09 ET | 10623 | 9.88 |
11:11 ET | 2950 | 9.965 |
11:13 ET | 1500 | 9.95 |
11:18 ET | 1150 | 9.935 |
11:22 ET | 3506 | 9.8946 |
11:24 ET | 511 | 9.87 |
11:26 ET | 1197 | 9.87 |
11:27 ET | 1600 | 9.89 |
11:29 ET | 3428 | 9.92 |
11:31 ET | 101 | 9.94 |
11:33 ET | 1399 | 9.955 |
11:36 ET | 556 | 9.95 |
11:38 ET | 600 | 9.92 |
11:40 ET | 600 | 9.92 |
11:44 ET | 500 | 9.9131 |
11:45 ET | 100 | 9.925 |
11:47 ET | 200 | 9.9 |
11:49 ET | 300 | 9.92 |
11:51 ET | 4352 | 10.04 |
11:54 ET | 1000 | 10.08 |
11:56 ET | 3301 | 10.095 |
11:58 ET | 1600 | 10.07 |
12:00 ET | 700 | 10 |
12:02 ET | 1100 | 9.95 |
12:03 ET | 1200 | 9.97 |
12:05 ET | 1044 | 10.01 |
12:09 ET | 100 | 9.98 |
12:12 ET | 800 | 9.985 |
12:14 ET | 796 | 9.95 |
12:16 ET | 300 | 9.97 |
12:18 ET | 1600 | 10 |
12:20 ET | 400 | 10 |
12:21 ET | 200 | 10.06 |
12:23 ET | 900 | 10.02 |
12:25 ET | 400 | 9.99 |
12:32 ET | 800 | 9.91 |
12:34 ET | 100 | 9.91 |
12:36 ET | 663 | 9.93 |
12:38 ET | 200 | 9.91 |
12:39 ET | 1822 | 9.93 |
12:41 ET | 1750 | 9.965 |
12:43 ET | 200 | 9.95 |
12:45 ET | 2900 | 9.93 |
12:48 ET | 300 | 9.93 |
12:50 ET | 455 | 9.92 |
12:52 ET | 1100 | 9.9 |
12:54 ET | 1988 | 9.92 |
12:56 ET | 300 | 9.92 |
12:57 ET | 2070 | 9.935 |
12:59 ET | 400 | 9.92 |
01:01 ET | 600 | 9.92 |
01:03 ET | 3613 | 9.99 |
01:06 ET | 600 | 9.985 |
01:08 ET | 100 | 9.99 |
01:12 ET | 500 | 10.02 |
01:15 ET | 100 | 10.035 |
01:17 ET | 400 | 10.02 |
01:19 ET | 400 | 10.09 |
01:21 ET | 300 | 10.09 |
01:24 ET | 1900 | 10.04 |
01:30 ET | 1100 | 10.06 |
01:32 ET | 1900 | 10.075 |
01:33 ET | 900 | 10.13 |
01:35 ET | 400 | 10.16 |
01:37 ET | 1562 | 10.14 |
01:39 ET | 4088 | 10.21 |
01:42 ET | 100 | 10.24 |
01:44 ET | 1000 | 10.22 |
01:46 ET | 2494 | 10.3 |
01:48 ET | 1646 | 10.27 |
01:50 ET | 1639 | 10.25 |
01:51 ET | 750 | 10.26 |
01:53 ET | 450 | 10.28 |
01:55 ET | 200 | 10.29 |
01:57 ET | 2802 | 10.27 |
02:00 ET | 943 | 10.27 |
02:02 ET | 362 | 10.23 |
02:04 ET | 700 | 10.25 |
02:06 ET | 200 | 10.26 |
02:08 ET | 200 | 10.25 |
02:09 ET | 950 | 10.26 |
02:11 ET | 2828 | 10.29 |
02:13 ET | 5941 | 10.26 |
02:15 ET | 100 | 10.28 |
02:18 ET | 1515 | 10.22 |
02:20 ET | 1046 | 10.19 |
02:22 ET | 160 | 10.17 |
02:24 ET | 1025 | 10.17 |
02:26 ET | 2100 | 10.17 |
02:27 ET | 1850 | 10.23 |
02:29 ET | 497 | 10.27 |
02:31 ET | 100 | 10.27 |
02:33 ET | 1300 | 10.24 |
02:36 ET | 4200 | 10.21 |
02:38 ET | 1922 | 10.2 |
02:40 ET | 2300 | 10.19 |
02:42 ET | 591 | 10.1703 |
02:44 ET | 1928 | 10.155 |
02:45 ET | 300 | 10.14 |
02:47 ET | 4700 | 10.14 |
02:49 ET | 1700 | 10.1394 |
02:51 ET | 200 | 10.15 |
02:54 ET | 6597 | 10.18 |
02:56 ET | 956 | 10.1604 |
02:58 ET | 402 | 10.17 |
03:00 ET | 1600 | 10.18 |
03:02 ET | 2600 | 10.23 |
03:03 ET | 1621 | 10.24 |
03:05 ET | 636 | 10.215 |
03:07 ET | 1547 | 10.2 |
03:09 ET | 3689 | 10.22 |
03:12 ET | 5429 | 10.17 |
03:14 ET | 1404 | 10.19 |
03:16 ET | 1328 | 10.27 |
03:18 ET | 1363 | 10.3133 |
03:20 ET | 1455 | 10.245 |
03:21 ET | 1466 | 10.28 |
03:23 ET | 900 | 10.29 |
03:25 ET | 933 | 10.3 |
03:27 ET | 400 | 10.3 |
03:30 ET | 2510 | 10.27 |
03:32 ET | 6728 | 10.32 |
03:34 ET | 1647 | 10.37 |
03:36 ET | 1576 | 10.4 |
03:38 ET | 4714 | 10.4 |
03:39 ET | 1205 | 10.43 |
03:41 ET | 3929 | 10.43 |
03:43 ET | 7109 | 10.415 |
03:45 ET | 5707 | 10.435 |
03:48 ET | 8765 | 10.49 |
03:50 ET | 14696 | 10.44 |
03:52 ET | 2600 | 10.4 |
03:54 ET | 1539 | 10.39 |
03:56 ET | 9696 | 10.39 |
03:57 ET | 12004 | 10.3 |
03:59 ET | 110996 | 10.36 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Replimune Group Inc | 695.0M | -3.2x | --- |
Olema Pharmaceuticals Inc | 688.0M | -6.1x | --- |
Prime Medicine Inc | 685.4M | -2.6x | --- |
Erasca Inc | 706.8M | -3.5x | --- |
Oric Pharmaceuticals Inc | 678.3M | -5.6x | --- |
Phathom Pharmaceuticals Inc | 681.9M | -2.6x | --- |
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $695.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-3.24 |
Book Value | $6.10 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.